
Jubilant FoodWorks (JFL) has said it will not renew its franchise agreement with US-based coffee-and-doughnut chain Dunkin’ in India once the current arrangement ends on 31 December 2026.
The two businesses signed a multiple-unit development franchise agreement (MUDFA) in February 2011, which granted JFL the rights to develop and run Dunkin’ outlets in the country.
In a filing, JFL stated it will “in an orderly and phased manner, evaluate and undertake such actions as may be considered appropriate in respect of its existing Dunkin’ brand operations, including rationalisation and/or cessation of certain operations and/or sale, transfer or disposal of assets and/or assignment or transfer of franchise rights, as may be required, in consultation with owners of Dunkin’ brand”.
JFL added that the move is not expected to have any material operational or financial impact.
Dunkin’s expansion in India has remained limited while JFL has increasingly concentrated on its Domino’s pizza business and newer formats such as the fried chicken chain Popeyes.
The Dunkin’ brand contributed 0.61% of the company’s revenue in the 2025 financial year and posted a loss of around Rs191m during the period.
Jubilant operated 27 Dunkin’ stores in India as of December 2025 and closed seven outlets over the previous year, according to its third-quarter investor presentation.
For the October–December quarter, the company reported profit of Rs709m ($7.49m), an increase of 65% from Rs429.1m a year earlier.
Earlier this week, JFL revealed that some outlets are facing restricted access to commercial liquefied petroleum gas (LPG) cylinders amid the ongoing conflict in West Asia.
The company added that it is working to conserve LPG and planning a transition to alternate energy sources such as electricity and piped natural gas (PNG).
"Jubilant FoodWorks to scrap Dunkin’ franchise arrangement in India" was originally created and published by Verdict Food Service, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
LATEST POSTS
- 1
Figure out How to Augment Your Rooftop Substitution Speculation - 2
Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats - 3
'Something Very Bad Is Going to Happen' is the Duffer Brothers' first project since 'Stranger Things.' It's also 'wildly insane.' - 4
Email Promoting Instruments for Compelling Efforts - 5
Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
Pick Your Number one Sort Of Music
More charges filed against ex-left-wing RAF member Daniela Klette
Quandoo to shut restaurant booking platform by end of 2026
Pfizer in $41.5 million settlement with Texas over ADHD drug for children
Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
CDC clarifies stance on vaccines and autism, stating no evidence supports the link
Father and son spending Christmas together after health scares
4K televisions for Extreme Film Watching Experience
The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program













